Division of Oral & Maxillofacial Surgery, Department of Surgery, New York Presbyterian Hospital - Weill Cornell Medical Center, New York, NY, USA.
Oral Medicine Unit, Sheba Medical Center, Tel Hashomer, Israel.
Support Care Cancer. 2022 Dec;30(12):10255-10262. doi: 10.1007/s00520-022-07443-2. Epub 2022 Nov 10.
Among the evidence-based agents outlined in the Multinational Association of Supportive Care in Cancer/International Society of Oral Oncology (MASCC/ISOO) mucositis guidelines, benzydamine and morphine are advised for the management of oral mucositis (OM) in certain cancer patients. This study is aimed to collect information from a group of highly experienced healthcare professionals in the field of oral mucositis about their clinical experience with these agents.
A survey questionnaire about the clinical experience with topical benzydamine and morphine to manage oral mucositis and their related adverse effects (AEs) was electronically distributed to the members of the Mucositis Study Group of MASCC/ISOO.
Eighty-eight entries were recorded (response rate 25%), and 54 entries submitted complete questionnaires about the drug-related AE (completion rate 65%) and were used for the data analysis. Of the respondents, 44% and 27.7% prescribed benzydamine and morphine to manage their patients' oral mucositis, respectively. Lack of availability in the respondent's country was the common reason for not prescribing benzydamine and morphine (18.9% and 5.4%, respectively); however, a large portion of the respondents indicated that 'another reason' stopped them from prescribing these agents (51.3% and 73%, respectively). AEs to benzydamine or morphine were observed by 25.9% and 12.9% of respondents, respectively, with mild numbness and tingling as the most common drug-related AE for both agents.
The use of topical benzydamine and morphine for the management of OM varies between countries. While relatively common, the AEs related to these agents are mild. Mitigating the barriers for prescribing them may increase their use.
在多国支持治疗癌症协会/国际口腔肿瘤学会（MASCC/ISOO）口腔黏膜炎指南中概述的循证药物中，苯扎氯铵和吗啡被建议用于某些癌症患者口腔黏膜炎（OM）的治疗。本研究旨在收集一组在口腔黏膜炎领域具有丰富经验的医疗保健专业人员的信息，了解他们使用这些药物的临床经验。
通过电子方式向 MASCC/ISOO 口腔黏膜炎研究组的成员分发了一份关于局部苯扎氯铵和吗啡治疗口腔黏膜炎及其相关不良反应（AE）的临床经验的调查问卷。
共记录了 88 条记录（回复率为 25%），其中 54 条记录提交了与药物相关 AE 的完整问卷（完成率为 65%），并用于数据分析。在回答者中，44%和 27.7%分别开处方苯扎氯铵和吗啡来治疗患者的口腔黏膜炎。缺乏药物在回答者所在国家的供应是不开处方苯扎氯铵和吗啡的常见原因（分别为 18.9%和 5.4%）；然而，很大一部分回答者表示，“另一个原因”阻止他们开这些药物（分别为 51.3%和 73%）。25.9%和 12.9%的回答者分别观察到苯扎氯铵和吗啡的 AE，两种药物最常见的药物相关 AE 均为轻度麻木和刺痛。
局部苯扎氯铵和吗啡在不同国家用于 OM 的治疗存在差异。虽然这些药物的 AE 相对常见，但都是轻度的。减轻开具这些药物的障碍可能会增加它们的使用。
